Belinda Cowling’s has focused on the investigation of the normal role of proteins in skeletal muscle, how these roles are disturbed in muscle disease, and identifying novel therapies for congenital myopathies.
Belinda completed her PhD at Monash University, Melbourne, Australia with Prof. Christina Mitchell, during which time she identified a novel regulator of skeletal muscle mass. She then moved to the IGBMC, France, to work with Dr. Jocelyn Laporte. During this time Belinda investigated the normal function of dynamin 2 in muscle, and how defects can cause centronuclear myopathy. They identified down regulation of dynamin 2 as a novel therapeutic target for myotubular myopathy.
Belinda’s research is now devoted to understanding muscle diseases and developing novel therapies, at the IGBMC in France.
Belinda contributed to the 2016 newsletter of ZNM-Zusammen Stark.
Presentations on family conferences
And this is her presentation:
Selected scientific publications
Belinda S. Cowling, Thierry Chevremont, Ivana Prokic, Christine Kretz, Arnaud Ferry, Catherine Coirault, Olga Koutsopoulos, Vincent Laugel, Norma B. Romero, and Jocelyn Laporte, Reducing dynamin 2 expression rescues X-linked centronuclear myopathy J Clin Invest.2014;124(3):1350–1363. doi:10.1172/JCI71206, http://www.jci.org/articles/view/71206/pdf#
Hichem Tasfaout,Suzie Buono, Shuling Guo, Christine Kretz, Nadia Messaddeq,
Sheri Booten, Sarah Greenlee, Brett P. Monia, Belinda S. Cowling & Jocelyn Laporte, Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice, Nature Communications 8, Article number: 15661 (2017) doi:10.1038/ncomms15661 https://www.nature.com/articles/ncomms15661
Both articles help to understand the therapeutic approach of the readjustment of the equilibrium between dynamin and myotubularin.